Anti-neprilysin drugs are mostly used for acute heart failure, cancer pain, hypertension, Alzheimer’s disease, and other diseases. The most commonly used anti-neprilysin is Sacubitril/valsartan thatis sold under the brand name Entrest. It consists of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker valsartan. Entrest was first manufactured by Novartis International AG- a biopharmaceutical compay. This drug has reduced rate of cardiovascular deaths and hospitalizations related to heart failure. Due to increasing prevalence of heart failure, the U.S. Food And Drug Administration granted fast track designation to Entresto in 2015, which supports the FDA’s efforts to facilitate the development and expedite the review of drugs to treat serious or life-threatening conditions and meet the unmet medical needs of patients.
Market Dynamics
Increasing prevalence of acute heart failure is expected to drive the antineprilysin market growth over the forecast period. For instance, according to the data published in September 2020, by PubMed, a free search engine for biological databases and medical reports, Heart failure affects more than 64 million people every year worldwide. Attempts to decrease its social and economic burden have become a major global public health priority.
Key features of the study:
- This report provides an in-depth analysis of the global anti-neprilysin market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global anti-neprilysin market based on the following parameters–Company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, Oceanic Pharmachem Pvt. Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global anti-neprilysin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti-neprilysin market
Detailed Segmentation:
- Global Anti-Neprilysin Market, By Drug Type:
- Sacubitril
- TD-0714
- STR-324
- PL-265
- LHW-090
- Global Anti-Neprilysin Market, By Indication:
- Acute Heart Failure
- Cancer Pain
- Hypertension
- Alzheimer’s Disease
- Others
- Global Anti-Neprilysin Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Anti-Neprilysin Market, By Region:
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- BIOPROJET
- Novartis AG
- Pharmaleads SA
- Theravance Biopharm
- Cipla Inc
- Oceanic Pharmachem Pvt. Ltd.
